Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 14Myelodysplastic Syndromes 7Myeloproliferative Disorders 3Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Myelomonocytic, Chronic 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1GATA2 Deficiency 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1BRCA1 Mutation 1Anemia, Refractory, with Excess of Blasts 1Allogeneic Stem Cell Transplantation 1

Interventions

ruxolitinib 1iadademstat 1fludarabine phosphate 1decitabine and cedazuridine drug combination 1Whole-Body Irradiation 1Tacrolimus 1Specimen Handling 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Methotrexate 1Melphalan 1Etoposide 1Cyclosporine 1Cyclophosphamide 1CPI-0610 1Busulfan 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thrombocythemia, Essential × decitabine and cedazuridine drug combination × 30 days × Clear all
NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡